Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Shanghai AiyingshiLtd Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Shanghai AiyingshiLtd şirketinin toplam hissedar öz sermayesi CN¥1.1B ve toplam borcu CN¥427.5M olup, bu da borç-öz sermaye oranını 37.2% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CN¥2.6B ve CN¥1.4B dir. Shanghai AiyingshiLtd 'in FAVÖK'ü CN¥118.5M faiz karşılama oranı -33.8 dur. Şirketin CN¥600.2M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

37.2%

Borç/özkaynak oranı

CN¥427.55m

Borç

Faiz karşılama oranı	-33.8x
Nakit	CN¥600.21m
Eşitlik	CN¥1.15b
Toplam yükümlülükler	CN¥1.43b
Toplam varlıklar	CN¥2.57b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Shanghai Aiyingshi Co.,Ltd's (SHSE:603214) Shares Bounce 30% But Its Business Still Trails The Market

Sep 24

Shanghai AiyingshiLtd (SHSE:603214) Will Pay A Larger Dividend Than Last Year At CN¥0.35

May 21

We Like Shanghai AiyingshiLtd's (SHSE:603214) Earnings For More Than Just Statutory Profit

Apr 09

Improved Earnings Required Before Shanghai Aiyingshi Co.,Ltd (SHSE:603214) Stock's 26% Jump Looks Justified

Mar 08

There Are Reasons To Feel Uneasy About Shanghai AiyingshiLtd's (SHSE:603214) Returns On Capital

Feb 28

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 603214 'nin kısa vadeli varlıkları ( CN¥1.7B ) kısa vadeli yükümlülüklerini ( CN¥1.2B ) aşıyor.

Uzun Vadeli Yükümlülükler: 603214 şirketinin kısa vadeli varlıkları ( CN¥1.7B ) uzun vadeli yükümlülüklerini ( CN¥203.2M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 603214 şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: 603214 şirketinin borç/öz sermaye oranı son 5 yılda 10.3% seviyesinden 37.2% seviyesine yükseldi.

Borç Kapsamı: 603214 'nin borcu işletme nakit akışı ( 71% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: 603214 ödediğinden daha fazla faiz kazandırıyor, dolayısıyla faiz ödemelerinin karşılanması bir sorun teşkil etmiyor.

Shanghai AiyingshiLtd Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Upcoming dividend of CN¥0.11 per share

Shanghai Aiyingshi Co.,Ltd to Report Q3, 2024 Results on Oct 25, 2024

Now 25% overvalued after recent price rise

Shanghai Aiyingshi Co.,Ltd's (SHSE:603214) Shares Bounce 30% But Its Business Still Trails The Market

Investor sentiment improves as stock rises 16%

New minor risk - Earnings quality

Second quarter 2024 earnings released: EPS: CN¥0.26 (vs CN¥0.28 in 2Q 2023)

Now 22% undervalued after recent price drop

Shanghai Aiyingshi Co.,Ltd to Report First Half, 2024 Results on Aug 23, 2024

Shanghai AiyingshiLtd (SHSE:603214) Will Pay A Larger Dividend Than Last Year At CN¥0.35

Dividend increased to CN¥0.35

First quarter 2024 earnings released: EPS: CN¥0.045 (vs CN¥0.019 in 1Q 2023)

We Like Shanghai AiyingshiLtd's (SHSE:603214) Earnings For More Than Just Statutory Profit

New minor risk - Earnings quality

Shanghai Aiyingshi Co.,Ltd, Annual General Meeting, Apr 25, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Shanghai Aiyingshi Co.,Ltd to Report Q1, 2024 Results on Apr 27, 2024

Shanghai Aiyingshi Co.,Ltd (SHSE:603214) commences an Equity Buyback Plan for 2,777,777 shares, representing 1.98% for CNY 50 million, under the authorization approved on March 6, 2024.

Improved Earnings Required Before Shanghai Aiyingshi Co.,Ltd (SHSE:603214) Stock's 26% Jump Looks Justified

There Are Reasons To Feel Uneasy About Shanghai AiyingshiLtd's (SHSE:603214) Returns On Capital

Investor sentiment improves as stock rises 15%

Investor sentiment deteriorates as stock falls 26%

Investor sentiment deteriorates as stock falls 16%

Shanghai Aiyingshi Co.,Ltd to Report Fiscal Year 2023 Results on Apr 03, 2024

New minor risk - Earnings quality

Third quarter 2023 earnings released: EPS: CN¥0.039 (vs CN¥0.026 in 3Q 2022)

Shanghai Aiyingshi Co.,Ltd to Report Q3, 2023 Results on Oct 26, 2023

Second quarter 2023 earnings released: EPS: CN¥0.28 (vs CN¥0.37 in 2Q 2022)

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.026 (vs CN¥0.096 loss in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.37 (vs CN¥0.25 in 2Q 2021)

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to CN¥19.11

Less than half of directors are independent

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Now 25% undervalued

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: CN¥0.096 loss per share (vs CN¥0.14 profit in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.25 (vs CN¥0.27 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.08 (vs CN¥0.06 in 1Q 2020)

Price target decreased to CN¥34.67

Consensus EPS estimates fall to CN¥1.06

Full year 2020 earnings released: EPS CN¥0.83 (vs CN¥1.10 in FY 2019)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

New 90-day low: CN¥19.28

New 90-day low: CN¥20.29

New 90-day low: CN¥23.49

New 90-day low: CN¥27.50

Shanghai Aiyingshi Co.,Ltd (SHSE:603214) agreed to acquire 48.53% stake in Nantong Xing'ai Maternal and Child Products Co., Ltd from Zhu Yuanqi for approximately CNY 110 million.

Analysts lower EPS estimates to CN¥0.90

Third quarter earnings released

Shanghai Aiyingshi Co.,Ltd to Report Q3, 2020 Results on Oct 22, 2020

New 90-day low: CN¥29.84

Earnings released

Shanghai Aiyingshi Co.,Ltd to Report First Half, 2020 Results on Aug 18, 2020

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin